Immuneering (IMRX) Liabilities and Shareholders Equity (2020 - 2024)
Immuneering (IMRX) has 5 years of Liabilities and Shareholders Equity data on record, last reported at $68.6 million in Q3 2024.
- For Q3 2024, Liabilities and Shareholders Equity fell 39.8% year-over-year to $68.6 million; the TTM value through Dec 2024 reached $233.6 million, down 47.97%, while the annual FY2023 figure was $102.6 million, 16.17% down from the prior year.
- Liabilities and Shareholders Equity reached $68.6 million in Q3 2024 per IMRX's latest filing, down from $77.1 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $166.7 million in Q4 2021 and bottomed at $38.4 million in Q4 2020.
- Average Liabilities and Shareholders Equity over 5 years is $110.4 million, with a median of $113.9 million recorded in 2023.
- Peak YoY movement for Liabilities and Shareholders Equity: skyrocketed 333.87% in 2021, then crashed 39.8% in 2024.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $38.4 million in 2020, then surged by 333.87% to $166.7 million in 2021, then fell by 26.6% to $122.4 million in 2022, then fell by 16.17% to $102.6 million in 2023, then crashed by 33.17% to $68.6 million in 2024.
- Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $68.6 million in Q3 2024, $77.1 million in Q2 2024, and $88.0 million in Q1 2024.